AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02883699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily undulating periodization resistance training
Description: Machine based daily undulating periodization resistance training 1 x per week
Study NCT01685645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlgiScan
Description: The AlgiScan device will be used to monitor analgesia during surgery. The integrated nociceptive stimulator will be used on both legs.
Study NCT01857557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Patients receiving exercise program in addition to usual headache care
Study NCT03279627 — intervention group
Intervention type: OTHER
Intervention: Diabetes Management Questionnaire
Description: Patients will be asked questions regarding their understanding of instructions for home diabetes management within 48 hours of hospital discharge. At 1 and 3 months, participants will be contacted to obtain information regarding ER visits or hospital readmissions.
Study NCT03652623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Description: In Phase 1, a PK study will be conducted to evaluate the differential PK of TDF/FTC in a cohort of transgender youth on cs-HT by conducting a PK trial of daily TDF/FTC among transgender women taking estradiol and transgender men taking testosterone (ages 15-24 years) using video-based directly observed therapy (DOT) to insure daily TDF/FTC adherence and maximize drug exposure.
Study NCT03842982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate.~Administration of the dose should be according the following schedule:~* 50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion.~* The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours.
Study NCT01768884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Study NCT01768884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02376959 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spiritist passe
Description: For a period of 5 min per week, the volunteers will remain in the supine position with their eyes closed, in a quiet environment with controlled light and temperature.~The applied intervention will consist of placing both hands in the classic Spiritist passe position for the stipulated 5-min period. Spiritist passe will be applied by volunteers with training and experience of more than two years with the technique.
Study NCT03859973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Tablet
Study NCT03859973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT04120298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: An individualised exercise programme supervised by a trained instructor
Study NCT03126552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necator americanus L3 larvae
Description: 50 Necator americanus L3 larvae
Study NCT00650481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin Chloride Extended-release Tablets 5 mg
Description: 4x5mg, single dose fasting
Study NCT00650481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ditropan XL® Tablets 5 mg
Description: 4x5mg, single dose fasting
Study NCT04096183 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ventilation of healthy volunteers
Description: Ventilation of healthy volunteers in different clinical situations
Study NCT00960583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: 24 group exercise sessions during 12 weeks
Study NCT04561505 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser enucleation of prostate
Description: surgical management of BPH by Holmium laser enucleation using 0.9% saline fluid for irrigation
Study NCT04561505 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monopolar transurethral resection of prostate
Description: surgical management of BPH by monopolar TURP using distilled water for irrigation
Study NCT00507325 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Sample
Description: Blood samples will be collected.
Study NCT00507325 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor Sample
Description: Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
Study NCT04285918 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous device closure
Description: If there is no relevant AF detected for 6 months during intermittent follow-up or ICM, device closure of PFO is recommended for high-risk PFOs but is decided ultimately at the discretion of the attending physician. If there is any relevant AF identified from ICM or other modalities during follow-up, adequate secondary prevention with anticoagulants should be carried out. All this process and decision making should be a part of routine clinical practice.
Study NCT01477021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01477021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1-specific T cells
Description: Given IV
Study NCT01477021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04502615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sand
Description: sand surface
Study NCT04502615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: artificial grass
Description: grass surface
Study NCT04502615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: firm ground
Description: firm surface
Study NCT01604746 — intervention group
Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Ross River Virus (RRV) Vaccine
Description: Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.
Study NCT00662961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periosteum
Description: Periosteum fixation
Study NCT00662961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone
Description: Bone tunnel fixation
Study NCT02160067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second generation BTDS patch
Study NCT02160067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: First generation BuTrans patch
Study NCT00960583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine follow-up
Description: Advice to stay active
Study NCT01172379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: Experimental 1 Drug: E2007~0.5 mg 1 tablet per day
Study NCT01115192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A
Description: Blephacura is a solution with liposomes and used for cleaning of the eye lid to treat blepharitis
Study NCT01172379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: Experimental 2 Drug: E2007~1.0 mg 1 tablet per day
Study NCT00482222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Study NCT00482222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT01172379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: Drug: E2007~2.0 mg 1 tablet per day
Study NCT01172379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo 1 tablet per day
Study NCT06008548 — intervention group
Intervention type: PROCEDURE
Intervention: TACE
Study NCT03246438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colonoscopy only
Description: Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to schedule colonoscopy.
Study NCT00482222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Study NCT00482222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00482222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Study NCT00482222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00482222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Study NCT00482222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT00482222 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: study of socioeconomic and demographic variables
Study NCT00482222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study of socioeconomic and demographic variables
Study NCT00482222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy
Study NCT00482222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00482222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant therapy
Study NCT00482222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00482222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study NCT00482222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT02556515 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interpositional arthroplasty (Burton-Pellegrini procedure)
Description: Burton-Pellegrini procedure
Study NCT03246438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colonoscopy outreach + mailed FIT follow-up
Description: Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to either schedule colonoscopy or to complete the enclosed mailed FIT kit.
Study NCT02466880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: A 15-30 minute diabetes self-management session. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
Study NCT03158675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fractional carbon dioxide(CO2) laser
Description: -Fractional CO2 laser: Laser sessions will be performed at half month interval and it will be used with a wave length of 10,600nm.
Study NCT02556515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total joint replacement
Description: Total joint replacement
Study NCT02556515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elektra prosthesis
Description: Elektra prosthesis
Study NCT00865891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine Extended Release tablets 60 mg, single dose
Description: A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under fasting conditions
Study NCT00865891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADALAT® CC Extended Release Tablets 60 mg
Description: B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under fasting conditions
Study NCT01714102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo manufactured to mimic resveratrol tablet
Study NCT01714102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol PO BID for 30 days
Study NCT03246438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colonoscopy + Mailed FIT outreach and follow-up
Description: Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line OR complete the enclosed mailed FIT kit. Subjects who have not completed FIT or scheduled colonoscopy within 4 weeks will be receive a reminder letter to either schedule colonoscopy or complete the mailed FIT kit previously sent.
Study NCT01476436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate dietary advice
Description: Dietary advice
Study NCT01476436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continue usual diet
Description: Dietary advice
Study NCT03158675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: Topical corticosteroid will be applyed twice weekly on both sides for 4 months.
Study NCT03158675 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultraviolet B narrow band
Description: Ultraviolet B narrow band will be performed (wave length ranged from 300 to 320nm).The sessions will be performed twice weekly for 4 months.
Study NCT02609256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic infarct tissue aspiration
Description: The patient posed supine position to expose local skin and puncture point was located at 6.5 cm behind the hairline of the lesion side, and 5.0 cm lateral of midline. After routine skin preparation and disinfection, 5% lidocaine 2-5 ml was injected for local anesthesia. The skin was cut to expose periosteum by a scalpel. After skull was vertically drilled through with a 6mm diameter hole, a sterile tube with a needle in tube was put about 8 cm into centrum semiovale. The needle was put out and about 50ml necrosis brain tissue was aspirated by a 20 ml syringe. The tube was fixed into the skin about 2 cm after subcutaneous tunnel, and connected to the drainage bag. Surgical area was sterilized and wrapped by sterile gauze bandage.
Study NCT02609256 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Medical therapy
Description: osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc
Study NCT02609256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical therapy
Description: osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc
Study NCT01476436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continue usual diet
Description: Dietary advice
Study NCT02753725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: The intervention arm will comprise Fentanyl given at a dose of one microgram per kilogramme body weight administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed.
Study NCT01467622 — intervention group
Intervention type: PROCEDURE
Intervention: Chest tube removal
Description: Chest tube removal on the basis of local recommendations for postoperative chest tube management
Study NCT02753725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose per body weight,administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed
Study NCT00736073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: one dose of aprepitant (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
Study NCT00736073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one dose of placebo (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
Study NCT03566212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Syringe
Description: local anesthesia was administered in first group using Conventional syringe
Study NCT03566212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Camouflage Syringe
Description: local anesthesia was administered in second group using Camouflage syringe
Study NCT02662478 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Surgery
Description: Mid-point between the xiphoid and umbilicus was used to the entrance site of the telescope. Open trocar insertion was used in patients with history of open upper abdominal surgery; otherwise Veress needle established CO2 insufflations. The number, size and entry points of the other trocars were tailored according to the tumor location and size. In general, 2 to 4 additional trocars were used. All specimens were taken out of the abdomen through a suprapubic transverse incision in a sterile bag. Resection technique was determined by the size, number, location of the lesion, and surgical anatomy of the stomach. Lymph node dissection was not done as it is unnecessary.
Study NCT04845295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Both experimental groups performed two exercises to target elbow flexor and knee extensor muscles: biceps curl on a Scott bench and parallel barbell squat, respectively. All sessions were performed at the same time (13-15 h), with a minimum 48 h rest between sessions on the same days during the week. For both groups, the intensity of load (1RM%) and number of sets were as follows: in the first three weeks the subjects exercises with ̴ 60% of 1RM in 3 sets, while during the next four weeks the load was set at ̴ 70% of 1RM in 4 sets. All repetitions were performed until muscular failure. The pause between sets was 2 minutes.
Study NCT01933386 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SoundBite
Description: Non-surgical removable bone conduction device via the teeth.
Study NCT03477786 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: drug adjustment and behavioral modification
Description: anti-hypertension drug prescription by physician and case management by health educator
Study NCT03477786 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: drug adjustment and behavioral modification
Description: anti-hypertension drug prescription by physician and case management by health educator
Study NCT03820791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of a poster in patients' rooms
Description: Patients and their caregivers will be exposed to the poster for one month
Study NCT03941743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Given PO
Study NCT03941743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod Hydrochloride
Description: Given PO
Study NCT03941743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02328976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional Magnetic Resonance Imaging (fMRI)
Description: both chronic and episodic patients with migraine have a specific functional Magnetic Resonance Imaging (fMRI)
Study NCT00183456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-oriented intervention
Description: The peer-oriented intervention program emphasized social identity and the goals of protecting family and community. The peer program also trained participants to provide HIV/STD education to their peers.
Study NCT00183456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group cognitive behavioral therapy (CBT)
Description: Group CBT will focus on teaching ways to modify thoughts and behaviors associated with risky sexual behaviors.
Study NCT06645340 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length
Description: This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length, and routine laboratory parameters.
Study NCT03288298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luteolin
Description: flavonoid natural extract
Study NCT03288298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nano-luteolin
Description: nanoparticles of luteolin
Study NCT01256541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kristalose
Description: The dosing regimen of Kristalose will be nine 20-gram doses (one dose every 30 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
Study NCT04375306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFR guided CABG
Description: All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the experimental arm the decision to revascularize will be based on RFR.